According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
|Articles|February 9, 2018
Moisturizing: False claims and problematic ingredients
Dermatologists recommend moisturizers for patients who suffer from atopic dermatitis, contact dermatitis and psoriasis. Some over-the-counter moisturizers contain allergens patients should avoid. For details, print our table-of-the-month.
Advertisement
Dermatologists recommend moisturizers for patients who suffer from atopic dermatitis, contact dermatitis and psoriasis. Some over-the-counter moisturizers contain allergens patients should avoid. For details, print our table-of-the-month.
Advertisement
Related to this article
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
5